

ANESTHESIOLOGY GRAND ROUNDS

Provided by Rutgers NJMS, Department of Anesthesiology

“Bental Procedure and Dextrocardia: Anesthesia Considerations”

MSB B-552 & via Webex

9-25-2024 / 7:00am to 8:00am

Adarsh Menon, MD

CA-2 Resident

Department of Anesthesiology

Learning Objectives

At the conclusion of this activity, participants should be better able to:

- Identify the indications/contraindications for new modalities in the diagnosis and treatment of conditions presented at each session.
- Describe new management and prevention strategies used for selected medical problems and types of patients.
- Discuss new developments and/or techniques being used in current scientific research.

Target Audience

This activity is designed for anesthesiologists, residents, and fellows involved in the administration of / management of complications related to anesthesia.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Adarsh Menon, MD has no relevant financial relationships with ineligible companies.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Alex Bekker, MD, PhD and George Tewfik, MD, MBA have no relevant financial relationships with ineligible companies to disclose.

Rutgers Health CE Staff: Patrick Dwyer and Elizabeth Ward have no relevant financial relationships with ineligible companies to disclose.